Since PPARγ has been implicated in the pathology of numerous diseases (including obesity, diabetes, atherosclerosis and cancer) and miR-27a has been found to suppress PPARγ; it appears that miR-27a could be a novel therapeutic target against metabolic complications associated with obesity as well as cancer. Here, PPARG is linked to Obesity.